AC Immune Initiates Phase 1 Clinical Trial of NLRP3 Inhibitor

Core Insights - AC Immune SA has initiated a Phase 1 clinical trial for ACI-19764, a small molecule NLRP3 inflammasome inhibitor, with the first participant dosed [2][4] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACI-19764 in healthy volunteers, with initial data expected in the second half of 2026 [4][7] Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases [2][7] - The company has a strong pipeline of first- and best-in-class assets, supported by two clinically validated technology platforms, SupraAntigen® and Morphomer® [8] Product Details - ACI-19764 is an orally available, highly brain-penetrant small molecule that specifically inhibits the NLRP3 inflammasome, showing high potency and selectivity in preclinical studies [6][7] - Preclinical data indicate that ACI-19764 has a competitive profile, demonstrating significant inhibition of neuroinflammation and potential for broad application in both metabolic and neurological therapeutic areas [5][6] Clinical Trial Design - The Phase 1 trial consists of two parts: Part A will assess single ascending doses, while Part B will evaluate multiple ascending doses [4] - Primary outcome measures include safety, tolerability, and pharmacokinetics, with secondary measures focusing on target engagement and exploratory endpoints related to immune system biomarkers [4][6]